CN111588729A - Application of beta-nicotinamide mononucleotide in products for preventing alopecia or promoting hair growth - Google Patents
Application of beta-nicotinamide mononucleotide in products for preventing alopecia or promoting hair growth Download PDFInfo
- Publication number
- CN111588729A CN111588729A CN202010549459.2A CN202010549459A CN111588729A CN 111588729 A CN111588729 A CN 111588729A CN 202010549459 A CN202010549459 A CN 202010549459A CN 111588729 A CN111588729 A CN 111588729A
- Authority
- CN
- China
- Prior art keywords
- hair growth
- preventing
- group
- promoting hair
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003779 hair growth Effects 0.000 title claims abstract description 40
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 37
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 230000001737 promoting effect Effects 0.000 title claims abstract description 29
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 21
- 230000003658 preventing hair loss Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000004604 Blowing Agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 27
- 210000003780 hair follicle Anatomy 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 9
- 230000012010 growth Effects 0.000 abstract description 6
- 230000037396 body weight Effects 0.000 abstract description 5
- 210000001732 sebaceous gland Anatomy 0.000 abstract description 5
- 230000002500 effect on skin Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000003676 hair loss Effects 0.000 description 12
- 208000024963 hair loss Diseases 0.000 description 11
- 210000004209 hair Anatomy 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000004631 alopecia areata Diseases 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 206010001766 Alopecia totalis Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000011897 Deaf-Blind disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses an application of beta-nicotinamide mononucleotide in a product for preventing alopecia or promoting hair growth, and relates to the technical field of products for preventing alopecia or promoting hair growth, and research results of the invention show that the body weights of mice in a control group and a test group in the whole test period are not obviously different, the growth condition of the mice is good, and the NMN has no toxic or side effect; compared with the blank group and the model group, after 8 weeks of high-dose gastric lavage, the hair growth of the mice is more compact, the number of hair follicles in the dermal layer of the depilated area of the high-dose group is slightly reduced, the residual hair follicle structure is basically complete, the sebaceous glands are slightly reduced, the improvement is not obvious in the low-dose group, and the NMN can promote the hair growth of the depilated mice.
Description
Technical Field
The invention relates to the technical field of products for preventing alopecia or promoting hair growth, in particular to application of beta-nicotinamide mononucleotide in products for preventing alopecia or promoting hair growth.
Background
beta-Nicotinamide Mononucleotide (NMN), the full name nicotinamid mononuleotide, is a naturally occurring biologically active nucleotide, and there are 2 forms of NMN that occur irregularly, alpha and beta; the beta isomer is the active form of NMN and has a molecular weight of 334.221 g/mol. The food is widely distributed in daily food, vegetables such as cauliflower (0.25-1.12 mg NMN/100gm) and Chinese cabbage (0.0-0.90 mg NMN/100gm), fruits such as avocado (0.36-1.60 mg NMN/100gm), tomato (0.26-0.30 mg NMN/100gm), and meats such as raw beef (0.06-0.42 mg NMN/100gm) are rich in NMN.
NMN is a precursor of NAD +, the function of which is mainly embodied by NAD +, and the physiological reactions in which NAD + is specifically involved are mainly as follows: growth, DNA repair (PARPs mediated), SIRTs protein, NADP (H) synthesis. The decline of NAD + during aging is considered to be a major cause of diseases and disabilities such as hearing and vision loss, cognitive and motor dysfunction, immune deficiency, arthritis due to dysregulation of autoimmune inflammatory responses, metabolic disorders and cardiovascular diseases. Therefore, NMN supplementation increases NAD + levels in vivo, thereby delaying, ameliorating, and preventing aging-related phenotypes, or age-induced metabolic disorders, geriatric diseases, and the like.
Currently, hair loss and alopecia are common problems for people. Over 40% of men and nearly 15% of women experience some degree of hair loss or alopecia. Alopecia has a variety of causes, androgenetic alopecia accounts for more than 95% of all hair loss in male alopecia people, and testosterone and dihydrotestosterone levels play an important role. In short, individuals are more prone to hair loss as the androgen levels are higher.
Hereditary male pattern alopecia is the most common form of alopecia: it is manifested by a reduction in the number of hairs, and even baldness. Acute hair loss may be associated with chemotherapy, stress, severe malnutrition, iron deficiency, endocrine disorders, aids or intense radiation. Alopecia areata appears to be caused by autoimmunity (a mechanism of cellular regulation) and is characterized by the formation of "plaques" of varying size in one or more places of the body. Alopecia belongs to a form in which alopecia areata spreads to the entire scalp, and alopecia totalis belongs to a form in which alopecia areata spreads to the entire body. Mechanistically, in all forms of hair loss, hair loss is directly associated with diminished capacity, and the entry of the follicle into anagen is slowed or prevented, or the follicle is not maintained in anagen, so that hair shaft formation is reduced, slowed, or completely halted. The hair may enter the catagen phase without reaching sufficient growth in the anagen phase, thus forming a permanent short and thin state of hair (i.e., hair loss) because new hair follicles cannot be regenerated at present, and the treatment method focuses on preserving them.
Common treatment methods currently include topical treatment, drug treatment, and hair restoration surgery. Topical and oral treatment with minoxidil or finasteride is effective in treating androgenetic alopecia in some individuals, but not in all individuals. Although effective, both drugs have significant disadvantages. In addition to being expensive for most people, minoxidil is also a vasodilator, which if excessive is absorbed through the skin can cause changes in heart rate or blood pressure and chest pain. In men, finasteride pilatory agents can cause sexual dysfunction, breast tenderness, and possibly prostate hypertrophy. Although hair restoration surgery can be effective, it is extremely painful and costly. There is therefore a need for new substances which are effective in stimulating hair growth, are cost-effective and have few adverse side effects.
Disclosure of Invention
The invention provides application of beta-nicotinamide mononucleotide in a product for preventing alopecia or promoting hair growth, and solves the problems of poor treatment effect and side effect of existing alopecia and alopecia.
In order to solve the technical problems, the technical scheme of the invention is as follows:
use of beta-nicotinamide mononucleotide in a product for preventing hair loss or promoting hair growth.
Preferably, the dosage of the beta-nicotinamide mononucleotide is 1.0-10.0 mg/kg/d.
Preferably, the product for preventing hair loss or promoting hair growth is a medicament for preventing hair loss or promoting hair growth, a health product for preventing hair loss or promoting hair growth, or a nutritional food for preventing hair loss or promoting hair growth.
Preferably, the alopecia-preventing or hair-growth-promoting agent is an oral preparation, an intravenous injection, an inhalant or a nasal insufflation.
Preferably, the agent for preventing hair loss or promoting hair growth is a solid preparation or a liquid preparation.
Preferably, the medicament for preventing alopecia or promoting hair growth is a tablet, a capsule, a pill or an oral liquid.
Preferably, the alopecia prevention or hair growth promotion agent is in an immediate release formulation or a slow release formulation.
By adopting the technical scheme, the research result of the invention shows that the body weights of the mice in the control group and the test group are not obviously different in the whole test period, the growth condition of the mice is good, and the NMN has no toxic or side effect; compared with the blank group and the model group, after 8 weeks of high-dose gastric lavage, the hair growth of the mice is more compact, the number of hair follicles in the dermal layer of the depilated area of the high-dose group is slightly reduced, the residual hair follicle structure is basically complete, the sebaceous glands are slightly reduced, the improvement is not obvious in the low-dose group, and the NMN can promote the hair growth of the depilated mice.
Drawings
FIG. 1 is a diagram showing the changes in the histopathological morphology of the skin at the epilation area of an epilated mouse.
Detailed Description
The following further describes embodiments of the present invention with reference to the drawings. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Examples
Firstly, materials:
1. animals: SPF male mice weighing 18-20g
2. Sample preparation: NMN (beta-nicotinamide mononucleotide)
3. The instrument comprises the following steps: olympus microscope, electron microscope, single lens reflex camera
II, a test method:
1. preparing a model: 150 mg-kg of cyclophosphamide is injected into the unhairing area of the mouse once and subcutaneously-1And establishing a mouse depilation model.
2. Grouping administration: mice were divided into 4 groups according to the random number table: model, blank and low and high 2 dose groups of 8 individuals each. The model group is not processed after the model is built, and is allowed to grow naturally; a blank group, wherein the stomach is irrigated with normal saline; the lower and upper 2 dose groups were gavaged with aqueous NMN at 62 and 310mg/kg/d for 8 weeks.
3. The hair growth condition of the unhairing zone of each group of mice is observed by naked eyes 1 day before and 1, 2 and 8 weeks after the administration, and images are collected and stored by a Canon single lens reflex camera for later use.
4. HE staining observed changes in hair follicle morphology and number, 2 mice per group were randomly selected 1, 2, and 8 weeks after dosing, and sacrificed immediately to remove skin tissue from the area of hair loss. Fixing with 10% formalin, embedding with paraffin, slicing to 4-5um, and storing at-80 deg.C. The skin tissue in the depilatory area was stained by HE staining, gradient ethanol dehydrated, neutral gum mounted, and at each time point, 5 high power fields (× 400) were randomly selected for hair follicle counting, and the average was taken.
5. Results are expressed as x ± s, data were analyzed using SPSS17.0 statistical software, and one-way anova was applied for group comparisons.
Thirdly, test results:
1. weight change and hair growth
Before administration, hair in the depilated area of each group of mice naturally grows and is gray. The mice in each group had no significant change in body weight (P > 0.05) until the end of the experiment. After 1 week of administration, the mice in each group had the most severe hair loss, with substantially complete hair loss on the back and pink skin. After 2 weeks of administration, the local skin of the depilated area of the mice gradually changed from pink to grey-black, and compared with the model group and the blank group, the grey-black area of the skin of the depilated area of the mice in the high-dose group was obviously increased; whereas the low dose group had no apparent difference in the change in the dark gray area. After 8 weeks of administration, the depilated area of each group of mice appeared black and had more hair growing and extending gradually. The hair growth was more compact in the high dose group compared to the model and blank groups; while the low dose group was less dense.
As can be seen from the following table, the body weights of the control group and the test group mice in the whole test period have no significant difference, the growth condition of the mice is good, and the NMN has no toxic or side effect.
2. Effect of NMN on the number of Hair follicles in depilated mice
The results are shown in the table below, and the number of hair follicles was gradually decreased in each group of mice after depilation. At each time point, the number of follicles in the high dose group was significantly increased compared to the model group and the blank group, with statistical significance for the difference (P < 0.05); while the low dose group, although slightly increased, the difference was not statistically significant (P > 0.05).
In comparison with the set of models,*p is less than 0.05; in comparison with the blank set, the results,#P＜0.05
3. effect of NMN on histopathological morphological changes of skin at depilatory region of depilated mice
As shown in FIG. 1, after 2 weeks of administration, the hair follicle structure in the dermal layer of the depilated area was substantially intact in the model group and the blank group, but the follicular canal became enlarged and exhibited anaplastic metaphase change. The number of hair follicles, the degree of melanogenesis of hair follicle cells, was significantly increased in the high dose group compared to the model group and the blank group, and was not significantly different in the low dose group. After 8 weeks of administration, the number of hair follicles in the dermis of the depilatory area in the model group and the blank group is severely reduced, the hair follicles are sparsely distributed, the hair follicles are tiny, and the sebaceous glands are obviously reduced. Compared with the model group and the blank group, the number of hair follicles in the dermis layer of the depilatory area of the high-dose group is slightly reduced, the residual hair follicle structure is basically complete, and sebaceous glands are slightly reduced; while the low dose group did not significantly improve.
The research result shows that the body weights of the mice in the control group and the test group are not obviously different in the whole test period, the growth condition of the mice is good, and the NMN has no toxic or side effect; compared with the blank group and the model group, after 8 weeks of high-dose gastric lavage, the hair growth of the mice is more compact, the number of hair follicles in the dermal layer of the depilated area of the high-dose group is slightly reduced, the residual hair follicle structure is basically complete, the sebaceous glands are slightly reduced, the improvement is not obvious in the low-dose group, and the NMN can promote the hair growth of the depilated mice.
The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.
Claims (7)
1. Use of beta-nicotinamide mononucleotide in a product for preventing hair loss or promoting hair growth.
2. Use of β -nicotinamide mononucleotide according to claim 1 in a product for preventing hair loss or promoting hair growth, characterized in that: the dosage of the beta-nicotinamide mononucleotide is 1.0-10.0 mg/kg/d.
3. Use of β -nicotinamide mononucleotide according to claim 1 in a product for preventing hair loss or promoting hair growth, characterized in that: the product for preventing hair loss or promoting hair growth is a medicament for preventing hair loss or promoting hair growth, a health product for preventing hair loss or promoting hair growth or a nutritional food for preventing hair loss or promoting hair growth.
4. Use of β -nicotinamide mononucleotide according to claim 3 for preventing hair loss or promoting hair growth products, characterized in that: the medicine for preventing alopecia or promoting hair growth is oral preparation, intravenous injection, inhalant or nasal blowing agent.
5. Use of β -nicotinamide mononucleotide according to claim 3 for preventing hair loss or promoting hair growth products, characterized in that: the medicine for preventing alopecia or promoting hair growth is a solid preparation or a liquid preparation.
6. Use of β -nicotinamide mononucleotide according to claim 3 for preventing hair loss or promoting hair growth products, characterized in that: the method is characterized in that: the medicine for preventing alopecia or promoting hair growth is tablet, capsule, pill or oral liquid.
7. Use of β -nicotinamide mononucleotide according to claim 3 for preventing hair loss or promoting hair growth products, characterized in that: the medicament for preventing alopecia or promoting hair growth is in an immediate release dosage form or a slow release dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010549459.2A CN111588729A (en) | 2020-06-16 | 2020-06-16 | Application of beta-nicotinamide mononucleotide in products for preventing alopecia or promoting hair growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010549459.2A CN111588729A (en) | 2020-06-16 | 2020-06-16 | Application of beta-nicotinamide mononucleotide in products for preventing alopecia or promoting hair growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111588729A true CN111588729A (en) | 2020-08-28 |
Family
ID=72186425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010549459.2A Pending CN111588729A (en) | 2020-06-16 | 2020-06-16 | Application of beta-nicotinamide mononucleotide in products for preventing alopecia or promoting hair growth |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111588729A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021098874A1 (en) * | 2019-11-21 | 2021-05-27 | 百瑞全球有限公司 | Hair care composition and preparation method therefor |
| CN113398236A (en) * | 2021-07-05 | 2021-09-17 | 北京健讯医药科技有限公司 | Microcapsule composition with alopecia preventing and nourishing effects and application thereof |
| CN113768861A (en) * | 2021-10-09 | 2021-12-10 | 热休(厦门)细胞生物科技有限公司 | Exosome beauty fluid with hair loss prevention and hair growth functions and preparation method thereof |
| JP2022024400A (en) * | 2020-07-28 | 2022-02-09 | エリジオンサイエンス株式会社 | Hair restorer/grower |
| CN114848625A (en) * | 2022-06-28 | 2022-08-05 | 遵义医科大学 | Application of Ferrostatin-1 in preparation of agent for promoting hair growth |
| CN115089553A (en) * | 2022-06-21 | 2022-09-23 | 澳美制药(苏州)有限公司 | Chewable tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697722A (en) * | 2015-10-02 | 2018-10-23 | 麦德龙国际生物科技有限责任公司 | The crystal form of β-nicotinamide mononucleotide |
| CN109908067A (en) * | 2019-04-11 | 2019-06-21 | 聂乐明 | For hair tonic and the composition prevented hair loss and its preparation method and application |
| CN112823778A (en) * | 2019-11-21 | 2021-05-21 | 百瑞全球有限公司 | Hair care compositions and methods of making the same |
-
2020
- 2020-06-16 CN CN202010549459.2A patent/CN111588729A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697722A (en) * | 2015-10-02 | 2018-10-23 | 麦德龙国际生物科技有限责任公司 | The crystal form of β-nicotinamide mononucleotide |
| CN109908067A (en) * | 2019-04-11 | 2019-06-21 | 聂乐明 | For hair tonic and the composition prevented hair loss and its preparation method and application |
| CN112823778A (en) * | 2019-11-21 | 2021-05-21 | 百瑞全球有限公司 | Hair care compositions and methods of making the same |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021098874A1 (en) * | 2019-11-21 | 2021-05-27 | 百瑞全球有限公司 | Hair care composition and preparation method therefor |
| JP2022024400A (en) * | 2020-07-28 | 2022-02-09 | エリジオンサイエンス株式会社 | Hair restorer/grower |
| CN113398236A (en) * | 2021-07-05 | 2021-09-17 | 北京健讯医药科技有限公司 | Microcapsule composition with alopecia preventing and nourishing effects and application thereof |
| CN113398236B (en) * | 2021-07-05 | 2022-07-29 | 北京健讯医药科技有限公司 | Microcapsule composition with alopecia preventing and nourishing effects and application thereof |
| CN113768861A (en) * | 2021-10-09 | 2021-12-10 | 热休(厦门)细胞生物科技有限公司 | Exosome beauty fluid with hair loss prevention and hair growth functions and preparation method thereof |
| CN115089553A (en) * | 2022-06-21 | 2022-09-23 | 澳美制药(苏州)有限公司 | Chewable tablet and preparation method thereof |
| CN114848625A (en) * | 2022-06-28 | 2022-08-05 | 遵义医科大学 | Application of Ferrostatin-1 in preparation of agent for promoting hair growth |
| CN114848625B (en) * | 2022-06-28 | 2024-02-06 | 遵义医科大学 | Application of Ferrosistatin-1 in preparation of hair growth promoting agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111588729A (en) | Application of beta-nicotinamide mononucleotide in products for preventing alopecia or promoting hair growth | |
| US20100172865A1 (en) | Methods of enhancing hair growth | |
| CN109432400A (en) | A kind of trichogenous composition and its application | |
| KR20100018119A (en) | Composition for hair tonic or treating or preventing hair loss | |
| US9622963B2 (en) | Methods for stimulating growth and preventing loss of human hair | |
| US20210393545A1 (en) | Natural product composition for stimulating hair growth | |
| US5728393A (en) | Process for combating adiposity and compositions which may be used for this purpose | |
| CN112137910A (en) | A cosmetic composition for strengthening hair root | |
| JP5166116B2 (en) | Hair restorer | |
| CN108272781B (en) | Application of cardamonin in preparing medicine for preventing and treating alopecia | |
| JP5216414B2 (en) | Hair restorer | |
| EP0387757A2 (en) | Use of 5'-deoxy-5'methylthioadenosine, S-adenosylmethionine and their salts in the preparation of pharmaceutical compositions favouring hair growth in subjects suffering from baldness | |
| JP2009091325A (en) | Hair growth agent | |
| CN112220794B (en) | Application of limonin in preventing alopecia and promoting hair growth | |
| JP2002284668A (en) | Preventive and therapeutic agent against darkening | |
| JP7135106B2 (en) | Scalp and hair composition | |
| JPH01242516A (en) | Hair tonic, hair shampoo and hair growing promoter | |
| CN113058026B (en) | Application of Kisspeptin-234 in promoting hair growth | |
| KR100308491B1 (en) | Composition for growthing hair | |
| KR102386651B1 (en) | Composition for preventing or treating hair loss comprising tiplaxtinin | |
| KR102406692B1 (en) | Composition for promoting hair growth comprising germinated gemmule of bean | |
| CN112915176B (en) | Alpinia katsumadai composition for preventing and treating alopecia | |
| CN109044996B (en) | Medical application of schisandrin | |
| CN117503748A (en) | Hair growth and hair loss prevention application of ethyl p-methoxycinnamate | |
| KR20090090758A (en) | Composition for preventing hair loss or promoting hair generation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200828 |